Home › Subarachnoid Hemorrhage › NCT06119061
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
Who can join
Ages 18 to 85 · All sexes
Full eligibility criteria
Inclusion Criteria: * Adult aged 18-85 years * Actively draining ventriculostomy Exclusion Criteria: * history of hypersensitivity to telavancin or similar agents * reduced renal function (estimated creatinine clearance \< 50/ml) at the time of consent * severe anemia (hemoglobin \< 7gm/dl) * vulnerable population (pregnant, prisoner) * concomitant antimicrobial therapy
About the study
The proposed study aims to evaluate the CNS penetration of telavancin in a critically ill population using cerebrospinal fluid (CSF) drawn from external ventricular drains (EVDs). Patients with EVDs were chosen as the target population because they frequently require prolonged admission to the intensive care unit and drainage of CSF in order to prevent hydrocephalus. The estimated sample size is 20 subjects. This is a prospective cohort of patients with SAH. Patients will be included if they have an in-dwelling EVD, aged 18-85 years old.
Subjects will receive telavancin 10mg/kg (maximum 1000mg) every 24 hours for 3 consecutive doses. Serial serum and CSF samples will be obtained. An 8-hour urine collection will be completed on study day 2 in order to define the patient's measured creatinine clearance.
What is being tested
- Telavancin Injection (drug)
Sponsor: Aaron Cook · Participants: 20 · Started: Jul 2, 2024
Contact the study team
- Aaron Cook, PharmD · Phone: 859-323-9258
Official record on ClinicalTrials.gov — NCT06119061
Locations in the U.S.
| Kentucky | University of Kentucky, Lexington |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.